Swiss National Bank’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-25,300
| Closed | -$492K | – | 2619 |
|
|
2023
Q2 | $492K | Hold |
25,300
| – | – | ﹤0.01% | 2537 |
|
|
2023
Q1 | $718K | Sell |
25,300
-3,600
| -12% | -$107K | ﹤0.01% | 2413 |
|
|
2022
Q4 | $845K | Buy |
28,900
+900
| +3% | +$28.6K | ﹤0.01% | 2424 |
|
|
2022
Q3 | $740K | Hold |
28,000
| – | – | ﹤0.01% | 2450 |
|
|
2022
Q2 | $1.24M | Buy |
28,000
+2,000
| +8% | +$91.9K | ﹤0.01% | 2238 |
|
|
2022
Q1 | $1.29M | Buy |
26,000
+1,600
| +7% | +$76.8K | ﹤0.01% | 2278 |
|
|
2021
Q4 | $1.24M | Hold |
24,400
| – | – | ﹤0.01% | 2347 |
|
|
2021
Q3 | $1.36M | Hold |
24,400
| – | – | ﹤0.01% | 2275 |
|
|
2021
Q2 | $1.04M | Sell |
24,400
-900
| -4% | -$37.1K | ﹤0.01% | 2465 |
|
|
2021
Q1 | $1.06M | Sell |
25,300
-1,100
| -4% | -$51.1K | ﹤0.01% | 2328 |
|
|
2020
Q4 | $1.23M | Hold |
26,400
| – | – | ﹤0.01% | 2189 |
|
|
2020
Q3 | $1.12M | Buy |
26,400
+500
| +2% | +$21.9K | ﹤0.01% | 2030 |
|
|
2020
Q2 | $1.24M | Buy |
25,900
+4,700
| +22% | +$234K | ﹤0.01% | 1976 |
|
|
2020
Q1 | $975K | Buy |
21,200
+400
| +2% | +$20.1K | ﹤0.01% | 1839 |
|
|
2019
Q4 | $1.25M | Hold |
20,800
| – | – | ﹤0.01% | 2018 |
|
|
2019
Q3 | $1.18M | Hold |
20,800
| – | – | ﹤0.01% | 1977 |
|
|
2019
Q2 | $1.16M | Sell |
20,800
-500
| -2% | -$26.1K | ﹤0.01% | 2032 |
|
|
2019
Q1 | $1.07M | Hold |
21,300
| – | – | ﹤0.01% | 2022 |
|
|
2018
Q4 | $858K | Buy |
21,300
+600
| +3% | +$30.9K | ﹤0.01% | 2088 |
|
|
2018
Q3 | $1.44M | Hold |
20,700
| – | – | ﹤0.01% | 1931 |
|
|
2018
Q2 | $1.57M | Buy |
20,700
+6,500
| +46% | +$409K | ﹤0.01% | 1872 |
|
|
2018
Q1 | $748K | Hold |
14,200
| – | – | ﹤0.01% | 2242 |
|
|
2017
Q4 | $759K | Hold |
14,200
| – | – | ﹤0.01% | 2239 |
|
|
2017
Q3 | $847K | Hold |
14,200
| – | – | ﹤0.01% | 2162 |
|
|
2017
Q2 | $1.12M | Sell |
14,200
-1,200
| -8% | -$98.1K | ﹤0.01% | 1985 |
|
|
2017
Q1 | $1.28M | Hold |
15,400
| – | – | ﹤0.01% | 1860 |
|
|
2016
Q4 | $1.22M | Buy |
15,400
+900
| +6% | +$65.4K | ﹤0.01% | 1900 |
|
|
2016
Q3 | $1.01M | Sell |
14,500
-600
| -4% | -$33.2K | ﹤0.01% | 1955 |
|
|
2016
Q2 | $586K | Buy |
15,100
+1,400
| +10% | +$58.3K | ﹤0.01% | 2268 |
|
|
2016
Q1 | $535K | Buy |
13,700
+2,600
| +23% | +$165K | ﹤0.01% | 2271 |
|
|
2015
Q4 | $984K | Hold |
11,100
| – | – | ﹤0.01% | 1832 |
|
|
2015
Q3 | $822K | Buy |
11,100
+1,600
| +17% | +$133K | ﹤0.01% | 1896 |
|
|
2015
Q2 | $768K | Buy |
+9,500
| New | +$619K | ﹤0.01% | 1961 |
|
Other funds holding EGRX
BIP
Swiss National Bank's EGRX Position: Q3 2023 in Review
Swiss National Bank sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 25,300 shares — an estimated $492K sold.
Swiss National Bank first reported a position in EGRX in Q2 2015 and held it in 33 quarters. The position peaked at $1.57M in Q2 2018. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.
- Swiss National Bank reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Swiss National Bank sold 25,300 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $492K.
- Swiss National Bank first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 33 quarters.
- Swiss National Bank's Eagle Pharmaceuticals, Inc. position peaked at $1.57M in Q2 2018.
- 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.
Based on Swiss National Bank's 13F filing for Q3 2023, filed 8 Nov 2023.